We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+7.07%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$7.57B
AUM Growth
+$643M
Cap. Flow
+$235M
Cap. Flow %
3.1%
Top 10 Hldgs %
16.13%
Holding
1,154
New
305
Increased
228
Reduced
235
Closed
370

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$71M
2
BAX icon
Baxter International
BAX
+$60.7M
3
TMUS icon
T-Mobile US
TMUS
+$60.1M
4
PRGO icon
Perrigo
PRGO
+$53.7M
5
NRG icon
NRG Energy
NRG
+$50.9M

Sector Composition

Rank Sector Weight
1 Healthcare 18.11%
2 Industrials 11.84%
3 Consumer Discretionary 11.65%
4 Technology 10.61%
5 Financials 10.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AGN
26
DELISTED
Allergan plc
AGN
$51.1M 0.67%
198,532
+99,638
+101% +$24.9M
ECL icon
27
Ecolab
ECL
$78.1B
$50.7M 0.67%
485,025
+330,224
+213% +$36.1M
YUM icon
28
Yum! Brands
YUM
$41.8B
$49.5M 0.65%
944,417
+726,572
+334% +$37.8M
VRTX icon
29
Vertex Pharmaceuticals
VRTX
$121B
$49.4M 0.65%
+416,111
New +$46.9M
NRG icon
30
NRG Energy
NRG
$28.3B
$48.6M 0.64%
1,804,599
+1,720,705
+2,051% +$50.9M
AAP icon
31
Advance Auto Parts
AAP
$3.35B
$47.6M 0.63%
298,682
+92,068
+45% +$13.5M
CFG icon
32
Citizens Financial Group
CFG
$30.3B
$47.6M 0.63%
1,913,685
-467,200
-20% -$11.1M
SXT icon
33
Sensient Technologies
SXT
$5.26B
$47M 0.62%
778,652
-72,087
-8% -$4.13M
BIIB icon
34
Biogen
BIIB
$30B
$45.4M 0.6%
133,866
+120,934
+935% +$39.1M
LBTYA icon
35
Liberty Global Class A
LBTYA
$3.62B
$45.1M 0.6%
1,088,994
-83,546
-7% -$3.2M
MDVN
36
DELISTED
MEDIVATION, INC.
MDVN
$44.2M 0.58%
886,912
+814,326
+1,122% +$42.3M
AMZN icon
37
Amazon
AMZN
$2.92T
$44.1M 0.58%
2,844,780
+1,748,360
+159% +$27.2M
EBAY icon
38
eBay
EBAY
$50.6B
$43.5M 0.57%
1,842,949
+821,956
+81% +$18.7M
DFS
39
DELISTED
Discover Financial Services
DFS
$43.3M 0.57%
661,228
+278,780
+73% +$17.9M
MSFT icon
40
Microsoft
MSFT
$3.45T
$42.6M 0.56%
+917,869
New +$43.1M
SIVB
41
DELISTED
SVB Financial Group
SIVB
$41.7M 0.55%
359,657
+98,989
+38% +$10.8M
PTC icon
42
PTC
PTC
$15.8B
$41.7M 0.55%
1,137,422
+485,806
+75% +$18M
MDLZ icon
43
Mondelez International
MDLZ
$79.5B
$41.7M 0.55%
1,146,745
-315,493
-22% -$11.5M
LAZ icon
44
Lazard
LAZ
$4.13B
$39.1M 0.52%
781,189
+93,928
+14% +$4.66M
NLSN
45
DELISTED
Nielsen Holdings plc
NLSN
$39M 0.52%
872,613
+837,616
+2,393% +$35.9M
WOOF
46
DELISTED
VCA Inc.
WOOF
$39M 0.51%
799,550
-638,823
-44% -$28.7M
CST
47
DELISTED
CST Brands, Inc.
CST
$38.2M 0.5%
876,872
+570,315
+186% +$22.9M
FFIV icon
48
F5
FFIV
$22.9B
$37.8M 0.5%
289,872
+276,772
+2,113% +$34.5M
PARA
49
DELISTED
Paramount Global Class B
PARA
$36.7M 0.48%
663,370
-17,978
-3% -$958K
SHW icon
50
Sherwin-Williams
SHW
$82.7B
$36.2M 0.48%
412,386
-315,000
-43% -$24.8M

Similar funds

Marshall Wace's Q4 2014 Portfolio in Review

As of Q4 2014, Marshall Wace held 1,154 positions worth $7.57B, up 9.3% from $6.93B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Marshall Wace deployed $235M of net new capital in Q4 2014, opening 305 new positions and adding to 228 existing holdings. Its largest new stake was Baxter International: 1,557,838 shares worth $62M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Alibaba, an estimated $68.2M trimmed.

  • Marshall Wace's largest Q4 2014 buy was Baxter International: 1,557,838 shares worth $62M.
  • Marshall Wace added most to Allergan Inc in Q4 2014, an estimated $71M increase.
  • Marshall Wace's biggest Q4 2014 reduction was Alibaba, cutting an estimated $68.2M.
  • Marshall Wace fully exited Baker Hughes in Q4 2014, selling an estimated $40.5M.
  • Marshall Wace's ten largest holdings make up 16% of its $7.57B portfolio in Q4 2014.
  • Marshall Wace opened 305 new positions and closed 370 in Q4 2014.
  • Marshall Wace's portfolio value rose 9.3% quarter-over-quarter to $7.57B.

Based on Marshall Wace's 13F filing for Q4 2014, filed 17 Feb 2015.